# GCNT1

## Overview
GCNT1 is a gene that encodes the enzyme glucosaminyl (N-acetyl) transferase 1, a type II membrane protein involved in glycosylation processes within the Golgi apparatus. This enzyme plays a critical role in the synthesis of core 2 O-glycans by catalyzing the addition of N-acetylglucosamine to core 1 O-glycans, forming complex branched glycan structures essential for various cellular functions, including cell-cell interactions and signaling (Osborn2017Enzymatic; Gao2012Glycosylation). The activity of GCNT1 is crucial for the generation of selectin ligands, such as sialyl Lewis X, which are important for leukocyte trafficking and immune responses (Hobbs2017Regulation). Additionally, GCNT1 has significant implications in cancer biology, where its altered expression is associated with tumor progression and metastasis, particularly in prostate and gastric cancers (Hodgson2023The; Shen2019A). The gene's regulation and interactions with other proteins underscore its importance in maintaining cellular homeostasis and its potential as a therapeutic target.

## Structure
The human GCNT1 protein consists of 428 amino acids and is predicted to have a type II membrane topology. This structure includes an N-terminal cytoplasmic domain of 9 residues, a transmembrane segment of 23 residues, and a stem region followed by a catalytic domain. The catalytic domain spans from amino acids 38 to 428, which is crucial for its enzymatic function in synthesizing core2 O-glycans (Unknownauthors2014Handbook).

GCNT1 is involved in the formation of core2 structures in O-glycans, which are important for various biological processes, including T cell activation and cancer metastasis (Unknownauthors2014Handbook). The enzyme's activity is essential for forming selectin ligands, which modulate cell-cell interactions (Unknownauthors2014Handbook).

While the context does not provide detailed information on the secondary, tertiary, or quaternary structures of GCNT1, it highlights the importance of the catalytic domain and its role in glycosylation. The context also does not mention specific post-translational modifications or splice variant isoforms for GCNT1. The structural information provided focuses primarily on the enzyme's functional domains and their biological significance.

## Function
The GCNT1 gene encodes an enzyme known as glucosaminyl (N-acetyl) transferase 1, which is crucial for the synthesis of core 2 O-glycans. This enzyme catalyzes the addition of N-acetylglucosamine to core 1 O-glycans, a process essential for the formation of complex branched glycan structures. These structures are important for various cellular functions, including cell-cell interactions and signaling (Osborn2017Enzymatic; Gao2012Glycosylation).

In healthy human cells, GCNT1 is active in the Golgi apparatus, where it influences protein glycosylation. This activity is critical for the generation of functional ligands for selectins, such as sialyl Lewis X, which mediate the rolling of leukocytes on endothelial cells, a key step in leukocyte extravasation during immune responses (Hobbs2017Regulation). The enzyme's role in glycosylation is also important for the trafficking of memory CD8+ T cells into inflamed tissues, as it facilitates the synthesis of ligands necessary for cell adhesion and migration (Osborn2017Enzymatic).

GCNT1's function is regulated by cytokines like IL-15, which enhance its expression and activity, thereby promoting the synthesis of core 2 O-glycans and supporting immune cell trafficking (Osborn2017Enzymatic).

## Clinical Significance
GCNT1 (glucosaminyl (N-acetyl) transferase 1) plays a significant role in the progression of several cancers due to its involvement in glycosylation processes. In prostate cancer, GCNT1 is upregulated, particularly in aggressive and metastatic forms, contributing to tumor growth and altered glycosylation patterns. This upregulation is associated with increased expression of core 2 branched O-glycans and the cancer-associated sialyl Lewis X (sLeX) glycan, which are linked to enhanced cell adhesion and metastasis (Hodgson2023The; Munkley2016The). GCNT1 overexpression also correlates with the downregulation of the epithelial-mesenchymal transition (EMT) pathway, potentially affecting metastatic potential (Hodgson2023The).

In gastric cancer, GCNT1 serves as a biomarker, particularly in early-stage and high microsatellite instability (MSI-H) patients. Its expression is significantly altered, providing diagnostic potential with high sensitivity and specificity (Shen2019A). The enzyme's role in forming core 2 O-glycans is crucial for the expression of sialyl Lewis antigens, which facilitate cancer cell metastasis by interacting with selectins (Shen2019A).

GCNT1 is also implicated in immune responses, particularly in T cell activation and Notch signaling. Its expression is upregulated in response to Notch signals, influencing the glycosylation of CD43, a marker for T cell activation in contexts such as graft-versus-host disease (Perkey2020GCNT1Mediated).

## Interactions
GCNT1, also known as core 2 N-acetylglucosaminyltransferase 1 (C2GnT1), is involved in several protein interactions that are crucial for its function and localization within the Golgi apparatus. One significant interaction is with Golgi phosphoprotein 3 (GOLPH3), which is essential for the Golgi retention of C2GnT1. This interaction is mediated through the C-terminal region of C2GnT1, specifically involving a motif (LLRRR9) that is critical for its Golgi localization. Mutations in this motif disrupt the interaction, leading to mislocalization of C2GnT1 to the endoplasmic reticulum (Ali2012Golgi).

C2GnT1 also interacts with non-muscle myosin IIA (NMIIA), which is involved in its recycling and transport between the Golgi and the endoplasmic reticulum. This interaction is crucial for the proper localization and function of C2GnT1, as NMIIA binds to the cytoplasmic tail of C2GnT1, facilitating its transport and potentially its degradation via the proteasome (Petrosyan2012Nonmuscle).

These interactions highlight the role of GCNT1 in cellular processes such as glycosylation and cell adhesion, emphasizing its importance in maintaining Golgi structure and function.


## References


[1. (Hobbs2017Regulation) Samuel J. Hobbs and Jeffrey C. Nolz. Regulation of t cell trafficking by enzymatic synthesis of o-glycans. Frontiers in Immunology, May 2017. URL: http://dx.doi.org/10.3389/fimmu.2017.00600, doi:10.3389/fimmu.2017.00600. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2017.00600)

[2. (Gao2012Glycosylation) Yin Gao, Vishwanath B. Chachadi, Pi-Wan Cheng, and Inka Brockhausen. Glycosylation potential of human prostate cancer cell lines. Glycoconjugate Journal, 29(7):525–537, July 2012. URL: http://dx.doi.org/10.1007/s10719-012-9428-8, doi:10.1007/s10719-012-9428-8. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10719-012-9428-8)

[3. (Munkley2016The) Jennifer Munkley, Ian G. Mills, and David J. Elliott. The role of glycans in the development and progression of prostate cancer. Nature Reviews Urology, 13(6):324–333, April 2016. URL: http://dx.doi.org/10.1038/nrurol.2016.65, doi:10.1038/nrurol.2016.65. This article has 82 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrurol.2016.65)

[4. (Unknownauthors2014Handbook) Handbook of glycosyltransferases and related genes. 2014. URL: http://dx.doi.org/10.1007/978-4-431-54240-7, doi:10.1007/978-4-431-54240-7. This article has 51 citations.](https://doi.org/10.1007/978-4-431-54240-7)

[5. (Ali2012Golgi) Mohamed F. Ali, Vishwanath B. Chachadi, Armen Petrosyan, and Pi-Wan Cheng. Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling golgi localization of core 2 n-acetylglucosaminyltransferase 1. Journal of Biological Chemistry, 287(47):39564–39577, November 2012. URL: http://dx.doi.org/10.1074/jbc.m112.346528, doi:10.1074/jbc.m112.346528. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m112.346528)

[6. (Hodgson2023The) Kirsty Hodgson, Margarita Orozco-Moreno, Emma Scott, Rebecca Garnham, Karen Livermore, Huw Thomas, Yuhan Zhou, Jiepei He, Abel Bermudez, Fernando Jose Garcia Marques, Kayla Bastian, Gerald Hysenaj, Emily Archer Goode, Rakesh Heer, Sharon Pitteri, Ning Wang, David J. Elliott, and Jennifer Munkley. The role of gcnt1 mediated o-glycosylation in aggressive prostate cancer. Scientific Reports, October 2023. URL: http://dx.doi.org/10.1038/s41598-023-43019-8, doi:10.1038/s41598-023-43019-8. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-43019-8)

[7. (Perkey2020GCNT1Mediated) Eric Perkey, Dave Maurice De Sousa, Léolène Carrington, Jooho Chung, Alexander Dils, David Granadier, Ute Koch, Freddy Radtke, Burkhard Ludewig, Bruce R. Blazar, Christian W. Siebel, Todd V. Brennan, Jeffrey Nolz, Nathalie Labrecque, and Ivan Maillard. Gcnt1-mediated o-glycosylation of the sialomucin cd43 is a sensitive indicator of notch signaling in activated t cells. The Journal of Immunology, 204(6):1674–1688, March 2020. URL: http://dx.doi.org/10.4049/jimmunol.1901194, doi:10.4049/jimmunol.1901194. This article has 23 citations.](https://doi.org/10.4049/jimmunol.1901194)

[8. (Petrosyan2012Nonmuscle) Armen Petrosyan, Mohamed F. Ali, Shailendra Kumar Verma, Helen Cheng, and Pi-Wan Cheng. Non-muscle myosin iia transports a golgi glycosyltransferase to the endoplasmic reticulum by binding to its cytoplasmic tail. The International Journal of Biochemistry &amp; Cell Biology, 44(7):1153–1165, July 2012. URL: http://dx.doi.org/10.1016/j.biocel.2012.04.004, doi:10.1016/j.biocel.2012.04.004. This article has 23 citations.](https://doi.org/10.1016/j.biocel.2012.04.004)

[9. (Osborn2017Enzymatic) Jossef F. Osborn, Jana L. Mooster, Samuel J. Hobbs, Michael W. Munks, Conrad Barry, John T. Harty, Ann B. Hill, and Jeffrey C. Nolz. Enzymatic synthesis of core 2 o-glycans governs the tissue-trafficking potential of memory cd8 + t cells. Science Immunology, October 2017. URL: http://dx.doi.org/10.1126/sciimmunol.aan6049, doi:10.1126/sciimmunol.aan6049. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciimmunol.aan6049)

[10. (Shen2019A) Qiujin Shen, Karol Polom, Coralie Williams, Felipe Marques Souza de Oliveira, Mariana Guergova-Kuras, Frederique Lisacek, Niclas G. Karlsson, Franco Roviello, and Masood Kamali-Moghaddam. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. eBioMedicine, 44:322–333, June 2019. URL: http://dx.doi.org/10.1016/j.ebiom.2019.05.044, doi:10.1016/j.ebiom.2019.05.044. This article has 49 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ebiom.2019.05.044)